Biodexa Pharmaceuticals Plc submitted a 6-K filing on February 24, 2025, indicating it will file annual reports under Form 20-F. The information is included as an exhibit but not filed under the Exchange Act provisions, ensuring it does not incur liabilities under Section 18.